Vera Therapeutics, Inc. (VERA)

41,32 -1,01 (-2,39%) Börsenschluss: 04:00PM EDT

Vera Therapeutics, Inc.

8000 Marina Boulevard
Suite 120
Brisbane, CA 94005
United States
650 770 0077
https://veratx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 51

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Marshall W. Fordyce M.D.	Founder, President, CEO & Director	910,14k	N/A	1975
Mr. Sean P. Grant M.B.A.	Chief Financial Officer	642k	N/A	1985
Mr. Joseph R. Young M.B.A.	Senior VP of Finance & Chief Accounting Officer	N/A	N/A	1973
Mr. Julien E. Capers J.D.	VP & Head of Legal	N/A	N/A	N/A
Ms. Kelly Rauber	VP & Head of Human Resources	N/A	N/A	N/A
Mr. Tom Doan	Senior Vice President of Development Operations	N/A	N/A	1972
Ms. Lauren Frenz	Chief Business Officer	N/A	N/A	1985
Dr. Neeraj Pakala M.B.A., Ph.D.	Senior VP and Head of Product Development & Manufacturing	N/A	N/A	N/A
Dr. Kerry Cooper M.D.	Senior Vice President of Medical Affairs	N/A	N/A	N/A
Dr. Robert M. Brenner M.D.	Chief Medical Officer	N/A	N/A	1968

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Corporate Governance

Vera Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 6, Vorstand: 6, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.